Under the terms of the agreement, Alcyone will receive $10M upfront & is eligible to receive up to $41M in development & commercial milestone. Biogen aims to improve the treatment experience for patients with neurological conditions
Biogen & Alcyone will jointly collaborate for the clinical development of the ThecaFlex DRx System for ASO therapies whereas Alcyone will be responsible for its manufacturing & commercialization
ThecaFlex DRx System is an implantable medical device developed for the subcutaneous delivery of ASO therapies into the intrathecal space for patients with a chronic neurological condition. Additionally, ThecaFlex DRx System is expected to be initially evaluated with Spinraza
Ref: Globenewswire | Image: Biogen
Related News:- Biogen Reports the US FDA’s Acceptance of Abbreviated BLA of BIIB800 (biosimilar, tocilizumab) for Rheumatoid Arthritis
